0
Signin
countryflagUS

18889881171

AAPL 165.84 0.5091% MSFT 400.96 0.461% GOOG 157.95 1.4321% GOOGL 156.28 1.4212% AMZN 177.23 1.4889% NVDA 795.18 4.3543% META 481.73 0.1372% TSLA 142.05 -3.4002% TSM 129.75 1.6053% LLY 731.33 0.6912% V 272.33 0.9452% AVGO 1224.46 1.6394% JPM 189.41 1.9429% UNH 491.23 -1.9755% NVO 125.26 2.0781% WMT 60.14 1.0247% LVMUY 168.89 0.4222% XOM 120.57 0.5756% LVMHF 851.89 0.4528% MA 456.75 0.2986%

Novavax Inc

Healthcare US NVAX

4.07USD
0.10(2.52%)

Last update at 2024-04-22T20:10:00Z

Day Range

3.914.13
LowHigh

52 Week Range

4.8513.70
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -653.64700M -1714.53600M -418.25900M -132.69400M -184.74800M
Minority interest - - - - -
Net income -657.93900M -1743.75100M -427.50500M -130.10200M -184.74800M
Selling general administrative 488.69M 298.36M 145.29M 34.42M 34.41M
Selling and marketing expenses - - - - -
Gross profit 696.31M 1146.29M 475.60M 18.66M 34.29M
Reconciled depreciation 29.05M 12.66M 4.88M 5.68M 8.16M
Ebit -644.73600M -1699.23700M -421.60400M -120.58100M -182.07700M
Ebitda -633.76700M -1686.57600M -416.71900M -138.61300M -173.91800M
Depreciation and amortization 10.97M 12.66M 4.88M -18.03200M 8.16M
Non operating income net other - -6.83300M 13.61M 1.50M 2.78M
Operating income -644.73600M -1686.57600M -416.71900M -120.58100M -173.91800M
Other operating expenses 2243.69M 2832.87M 892.32M 148.26M 208.21M
Interest expense 19.88M 21.13M 15.14M 12.19M 12.19M
Tax provision 4.29M 29.21M - - -
Interest income - - - 12.10M 10.94M
Net interest income -19.88000M -21.12700M -15.14500M -13.61200M -13.61200M
Extraordinary items - - - - -
Non recurring - - - -9.01600M -
Other items - - - - -
Income tax expense 4.29M 29.21M 9.25M -2.59200M 1.36M
Total revenue 1598.95M 1146.29M 475.60M 18.66M 34.29M
Total operating expenses 1341.05M 2832.87M 892.32M 148.26M 208.21M
Cost of revenue 902.64M - - 113.84M 173.80M
Total other income expense net -8.91100M -27.96000M -1.54000M -12.11300M 0.11M
Discontinued operations - - - - -
Net income from continuing ops -657.93900M -1743.75100M -418.25900M -132.69400M -184.74800M
Net income applicable to common shares -657.93900M -1743.75100M -418.25900M -132.69400M -184.74800M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 2258.68M 2576.75M 1582.48M 172.96M 207.98M
Intangible assets - 4.77M 5.72M 5.58M 6.54M
Earning assets - - - - -
Other current assets 1691.43M 2141.98M 441.82M 93.89M 107.47M
Total liab 2892.76M 2928.43M 955.27M 358.97M 375.91M
Total stockholder equity -634.07800M -351.67300M 627.21M -186.01700M -167.93500M
Deferred long term liab - - - 2.50M 2.50M
Other current liab 1521.21M 709.79M -327.56000M 19.95M 1.60M
Common stock 0.87M 0.76M 0.71M 0.32M 3.85M
Capital stock 0.87M 0.76M 0.71M 0.32M 3.85M
Retained earnings -4275.88900M -3617.95000M -1874.19900M -1431.80100M -1299.10700M
Other liab 185.02M 175.53M 3.36M 2.56M 11.19M
Good will 126.33M 131.48M 135.38M 51.15M 51.97M
Other assets 28.47M 16.57M 5.42M 1.08M 1.77M
Cash 1336.88M 1515.12M 553.40M 78.82M 70.15M
Cash and equivalents - - - - -
Total current liabilities 2459.94M 2390.32M 322.04M 25.80M 45.54M
Current deferred revenue 370.14M 1422.94M 273.23M 1.68M 10.01M
Net debt -787.10200M -1061.12500M -231.36300M 243.05M 249.03M
Short term debt 352.08M 130.53M 322.04M 1.26M 24.63M
Short long term debt 324.88M - 322.04M - -
Short long term debt total 549.78M 453.99M 322.04M 321.87M 319.19M
Other stockholder equity 3647.32M 3266.87M 2493.67M 1257.97M 1138.32M
Property plant equipment 400.49M 228.70M 179.95M 11.45M 28.43M
Total current assets 1703.39M 2155.12M 1248.20M 97.25M 119.28M
Long term investments - - - - -
Net tangible assets -760.40900M -487.92200M 486.11M -242.75200M -226.44300M
Short term investments - 0.00000M 157.65M 0.00000M 21.98M
Net receivables 82.38M 454.99M 262.01M 7.50M -70.32300M
Long term debt 166.47M 323.46M 322.04M 320.61M 319.19M
Inventory 36.68M -1956.96600M -166.67200M -82.96600M 11.97M
Accounts payable 216.52M 127.05M 54.33M 2.91M 9.30M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -6.37700M -1.35300M 7.02M -12.50800M -11.19100M
Additional paid in capital - - - - -
Common stock total equity - 0.76M 0.71M 0.32M 3.85M
Preferred stock total equity - - - - -
Retained earnings total equity - -3617.95000M -1874.19900M -1431.80100M -1299.10700M
Treasury stock - -85.10100M -41.80600M -2.58300M -2.45000M
Accumulated amortization - - - - -
Non currrent assets other 28.47M 56.69M 13.22M 7.53M 1.77M
Deferred long term asset charges - - - - -
Non current assets total 555.29M 421.63M 334.28M 75.71M 88.70M
Capital lease obligations 58.43M 130.53M 149.73M 1.26M -
Long term debt total - 323.46M 322.04M 320.61M 319.19M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -92.98500M 157.64M -157.64000M 22.02M 29.97M
Change to liabilities -132.51500M 1925.88M 434.71M -19.81600M -22.35400M
Total cashflows from investing activities -92.98500M 100.15M -377.77800M 38.49M 28.60M
Net borrowings 81.66M -127.90700M -96.06500M -96.06500M -96.06500M
Total cash from financing activities 324.99M 461.71M 984.76M 98.38M 102.81M
Change to operating activities - - - -4.20200M 1.21M
Net income -657.93900M -1743.75100M -418.25900M -132.69400M -184.74800M
Change in cash -179.41400M 879.52M 566.56M 0.22M -53.47200M
Begin period cash flow 1528.26M 648.74M 82.18M 81.96M 135.43M
End period cash flow 1348.85M 1528.26M 648.74M 82.18M 81.96M
Total cash from operating activities -415.93700M 322.95M -42.54100M -136.62300M -184.82500M
Issuance of capital stock 249.23M 564.86M 1075.44M 97.39M 100.06M
Depreciation 29.05M 12.66M 4.88M 5.68M 8.16M
Other cashflows from investing activities - - -165.51600M 18.33M 18.33M
Dividends paid - - - - -
Change to inventory -477.80100M -600.32600M -163.16100M -8.87200M -
Change to account receivables 249.17M -192.26500M -422.68900M -4.20200M 1.21M
Sale purchase of stock - 589.62M 1119.91M 98.38M 102.81M
Other cashflows from financing activities 169.35M 24.76M 205.20M 0.99M 2.75M
Change to netincome 574.10M 175.99M 111.53M 12.99M 11.48M
Capital expenditures 92.98M 57.49M 54.62M 1.86M 1.37M
Change receivables - 144.43M 245.86M - -
Cash flows other operating - -192.26500M -422.68900M -4.20200M 1.21M
Exchange rate changes - - - - -
Cash and cash equivalents changes - 884.81M 564.44M 0.25M -53.42400M
Change in working capital -361.15000M 1733.62M 12.02M -24.01800M -21.14200M
Stock based compensation 130.30M 183.63M 128.03M 17.05M 18.31M
Other non cash items 443.80M 136.79M 230.78M 6.29M -5.35300M
Free cash flow -508.92200M 265.46M -97.16300M -138.48000M -186.19700M

Fundamentals

  • Previous Close 3.97
  • Market Cap601.08M
  • Volume2290367
  • P/E Ratio-
  • Dividend Yield0.93%
  • EBITDA-574.86899M
  • Revenue TTM1049.76M
  • Revenue Per Share TTM11.70
  • Gross Profit TTM -156.04500M
  • Diluted EPS TTM-6.23

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
NVAX
Novavax Inc		 0.10 2.52% 4.07 - 1.63 0.56 49.52 0.16 -0.312
NVO
Novo Nordisk A/S		 2.55 2.08% 125.26 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 3.76 3.07% 126.26 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.64 1.43% 399.92 30.40 24.75 10.68 6.25 9.52 20.36
CSLLY
CSL Ltd		 2.35 2.71% 89.17 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

View All

Profile

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, Adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also focusing on products candidates for respiratory syncytial virus and malaria. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Novavax Inc

21 Firstfield Road, Gaithersburg, MD, United States, 20878

Key Executives

Name Title Year Born
Mr. Stanley Charles Erck Pres, CEO & Director 1948
Mr. James Patrick Kelly C.F.A. Exec. VP, CFO & Treasurer 1966
Mr. John A. Herrmann III Exec. VP, Chief Legal Officer & Corp. Sec. 1966
Mr. John Joseph Trizzino B.S., M.B.A. Exec. VP and Chief Bus. & Commercial Officer 1960
Dr. Gregory M. Glenn Pres of R&D 1954
Mr. Richard P. Crowley Exec. VP & COO 1957
Dr. Gale E. Smith Sr. VP of Discovery & Pre-Clinical Research and Chief Scientist 1950
Mr. Biegie Lee Sr. VP & Chief Information Officer NA
Mr. Troy Morgan Esq., J.D. Sr. VP & Chief Compliance Officer 1971
Ms. Erika S. Trahan Associate Director of Investor & PR NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).